UK liquid biopsy group Angle has released trial findings that indicate its Parsortix blood test has the potential to out-perform the current standard of care in detecting ovarian cancer.
The company said headline results from trials involving a total of 400 patients with a pelvic mass studies show the potential for Parsortix to discriminate between benign and malignant pelvic tumours with a degree of sensitivity, having correctly identifyied cancer in up to 95 percent of cases whilst achieving a higher specificity (low false positive rate) than existing tests.
Compared to CA125, at a high sensitivity the Parsortix result – which is RNA-based – had nearly double the specificity of the CA125 result, the firm noted.
“The test also offers key additional benefits over existing practice through the gene expression information it provides, which may help to further guide choices for targeted therapy in women with ovarian cancer,” and could “allow separate identification of patients with low malignant potential and/or other cancer types using a non-invasive liquid biopsy test,” noted Dr Richard Moore, director of the Gynecologic Oncology Division, University of Rochester Medical Center Wilmot Cancer Institute.
The positive data from the ANG-001 and ANG-003 trials will enable Angle to move into the next phase of development of a commercial blood test addressing an estimated market size of £300 million per annum, the firm said.
After it is optimised the performance of the test will be validated in another study designed to meet European CE Mark and US FDA regulatory requirements.
